CG Oncology, Inc. (CGON) Earnings Summary
CGON Earnings Beat Rate & Surprise History
CG Oncology, Inc. (CGON) has beaten EPS estimates in 2 of its last 8 reported quarters (+25%), and beaten revenue estimates in 5 of 9 (+56%).
On balance, analysts have tended to overestimate CGON's earnings. It is currently on a 2-quarter EPS miss streak. The stock has averaged -1.0% the trading day after an EPS beat (positive 50% of the time) and +1.5% after a miss. The average EPS surprise runs -11.2%, with the biggest beat at +16.6% and the biggest miss at -32.4%.
How often CGON has cleared Wall Street's bar, for EPS and revenue separately, companies can beat one and miss the other. See how analysts are rating it now →
Based on 8 quarters where a report date lines up with price history on record. Reaction day is determined from report timing, for after-market-close (AMC) reports, the reaction shows up the next trading day; for before-market-open (BMO) reports, it's the report day itself.
| Result | Next day | 5 trading days | 20 trading days |
|---|---|---|---|
| EPS beat | -1.0% (50% pos, n=2) | -3.5% (50% pos, n=2) | -2.4% (50% pos, n=2) |
| EPS miss | +1.5% (67% pos, n=6) | -2.1% (67% pos, n=6) | +6.0% (80% pos, n=5) |
Average earnings-day move (either direction): +4.0%. Largest on record: +8.6%.
Every quarter with reaction data, side by side. Rows where the surprise direction and the stock's move disagree are highlighted.
| Quarter | Report Date | EPS Surprise | Rev Surprise | Next-Day Move |
|---|---|---|---|---|
| Q2 '26 | Aug 6, 2026 | -32.4% | +220.7% | +3.4% |
| Q1 '26 | May 8, 2026 | -31.1% | +139.1% | +0.6% |
| Q4 '25 | Feb 27, 2026 | +16.6% | +406.7% | +4.8% |
| Q3 '25 | Nov 14, 2025 | -0.5% | +2700.0% | +8.6% |
| Q2 '25 | Aug 8, 2025 | -13.4% | -100.0% | +2.1% |
| Q1 '25 | May 13, 2025 | -23.2% | -72.4% | -3.9% |
| Q4 '24 | Mar 28, 2025 | -21.3% | +330.2% | -1.9% |
| Q3 '24 | Nov 12, 2024 | +15.8% | -62.0% | -6.8% |
A beat doesn't guarantee a rally, and a miss doesn't guarantee a drop, expectations already priced in can flip the reaction.
Beat/miss alone doesn't say how big, a company that beats by 0.1% every quarter behaves very differently from one that swings ±20%.
| Avg Surprise | Median | Largest Beat | Largest Miss | |
|---|---|---|---|---|
| EPS | -11.2% | -17.4% | +16.6% | -32.4% |
| Revenue | +390.6% | +139.1% | +2700.0% | -100.0% |
More analysts covering a stock generally means more scrutiny and (often) tighter estimates.
Average surprise size by fiscal quarter, some businesses are just more predictable in certain quarters than others.
| Fiscal Quarter | Avg EPS Surprise | Avg Revenue Surprise | Years on Record |
|---|---|---|---|
| Q1 | -27.1% | +33.3% | 2 |
| Q2 | -22.9% | +24.5% | 3 |
| Q3 | +7.7% | +1319.0% | 2 |
| Q4 | -2.3% | +368.4% | 2 |
Each quarter compared to the same fiscal quarter one year earlier, the standard way to strip out seasonality.
| Quarter | Report Date | EPS Growth | Revenue Growth |
|---|---|---|---|
| Q2 '26 | Aug 6, 2026 | -66.7% | — |
| Q1 '26 | May 8, 2026 | -57.8% | +1976.9% |
| Q4 '25 | Feb 27, 2026 | -23.8% | +396.7% |
| Q3 '25 | Nov 14, 2025 | -111.1% | +3783.7% |
| Q2 '25 | Aug 8, 2025 | -116.0% | -100.0% |
Objective, rule-based checks, not a subjective rating.
How often does CGON beat EPS estimates?
CG Oncology, Inc. has beaten EPS estimates in 2 of its last 8 reported quarters, a +25% beat rate. The average surprise is -11.2%.
How often does CGON beat revenue estimates?
CGON has beaten revenue estimates in 5 of its last 9 reported quarters, a +56% beat rate.
How does CGON's stock react to earnings?
Over 8 quarters with price data on record, CGON has averaged -1.0% the trading day after an EPS beat (positive 50% of the time) and +1.5% after a miss (positive 67% of the time).
What is CGON's biggest earnings surprise?
CGON's largest EPS beat on record is +16.6%, and its largest EPS miss is -32.4%.
Is CGON currently on an earnings beat or miss streak?
CGON is on a 2-quarter EPS miss streak. Its longest beat streak on record is 1 quarters; its longest miss streak is 4 quarters.
Do analysts usually underestimate or overestimate CGON?
Analysts have tended to overestimate CGON's results, based on a +25% EPS beat rate over the last 8 reported quarters.
Every reported quarter on record, estimate vs. actual.
| Quarter | Report Date | EPS Est | EPS Actual | EPS Surprise | Revenue Est | Revenue Actual | Revenue Surprise | Analysts |
|---|---|---|---|---|---|---|---|---|
| Q2 '26 | Aug 6, 2026 | -$0.68 | -$0.90 | -32.4% | $360.8K | $1.16M | +220.7% | 6 |
| Q1 '26 | May 8, 2026 | -$0.54 | -$0.71 | -31.1% | $453.0K | $1.08M | +139.1% | 7 |
| Q4 '25 | Feb 27, 2026 | -$0.62 | -$0.52 | +16.6% | $450.5K | $2.28M | +406.7% | 6 |
| Q3 '25 | Nov 14, 2025 | -$0.57 | -$0.57 | -0.5% | $59.4K | $1.67M | +2700.0% | 5 |
| Q2 '25 | Aug 8, 2025 | -$0.48 | -$0.54 | -13.4% | $101.3K | $0.00 | -100.0% | 4 |
| Q1 '25 | May 13, 2025 | -$0.37 | -$0.45 | -23.2% | $188.3K | $52.0K | -72.4% | 4 |
| Q4 '24 | Mar 28, 2025 | -$0.34 | -$0.42 | -21.3% | $106.7K | $459.0K | +330.2% | 2 |
| Q3 '24 | Nov 12, 2024 | -$0.32 | -$0.27 | +15.8% | $113.0K | $43.0K | -62.0% | 1 |
| Q2 '24 | — | — | -$0.25 | — | $209.7K | $111.0K | -47.1% | — |